<li>abiraterone<p>abiraterone increases levels of carvedilol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.</p></li><li>acebutolol<p>acebutolol and carvedilol both increase  serum potassium. Use Caution/Monitor.</p></li><li>aceclofenac<p>carvedilol and aceclofenac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aceclofenac decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>acemetacin<p>carvedilol and acemetacin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>acemetacin decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>albuterol<p>carvedilol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>aldesleukin<p>aldesleukin increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>alfuzosin<p>alfuzosin and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>aluminum hydroxide<p>aluminum hydroxide decreases levels of carvedilol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>amifostine<p>amifostine increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>amiloride<p>carvedilol and amiloride both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>amiodarone will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Monitor for signs of bradycardia or heart block when amiodarone and a beta adrenergic blocker are coadministered. Amiodarone should be used with caution in patients receiving a beta adrenergic blocker, particularly if there is suspicion of underlying dysfunction of the sinus node, such as bradycardia or sick sinus syndrome, or if there is partial AV block.<span><br><br></span>amiodarone, carvedilol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of cardiotoxicity with bradycardia.</p></li><li>amlodipine<p>carvedilol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>amobarbital decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of amobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.</p></li><li>amphetamine<p>amphetamine decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>arformoterol<p>carvedilol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>asenapine<p>asenapine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>asenapine and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>aspirin<p>carvedilol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>aspirin rectal<p>carvedilol and aspirin rectal both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin rectal decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.<span><br><br></span>carvedilol and aspirin/citric acid/sodium bicarbonate both increase  serum potassium. Use Caution/Monitor.</p></li><li>atazanavir<p>atazanavir increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypotension, bradycardia, AV block, and prolonged PR interval. Consider lowering beta blocker dose.</p></li><li>atenolol<p>atenolol and carvedilol both increase  serum potassium. Use Caution/Monitor.</p></li><li>avanafil<p>avanafil increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>bambuterol<p>carvedilol increases and bambuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of bambuterol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>bendroflumethiazide<p>carvedilol increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>betaxolol<p>betaxolol and carvedilol both increase  serum potassium. Use Caution/Monitor.</p></li><li>bismuth subsalicylate<p>bismuth subsalicylate, carvedilol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension.</p></li><li>bisoprolol<p>bisoprolol and carvedilol both increase  serum potassium. Use Caution/Monitor.</p></li><li>bosentan<p>bosentan will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>bosutinib<p>bosutinib increases levels of carvedilol by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>bumetanide<p>carvedilol increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>bupropion<p>bupropion will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>butabarbital decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butabarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.</p></li><li>butalbital<p>butalbital will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>butalbital decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butalbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.</p></li><li>calcium acetate<p>calcium acetate decreases effects of carvedilol by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>calcium carbonate<p>calcium carbonate decreases effects of carvedilol by unspecified interaction mechanism. Use Caution/Monitor.<span><br><br></span>calcium carbonate decreases levels of carvedilol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>calcium chloride<p>calcium chloride decreases effects of carvedilol by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>calcium citrate<p>calcium citrate decreases effects of carvedilol by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>calcium gluconate<p>calcium gluconate decreases effects of carvedilol by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>candesartan<p>candesartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, candesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>carbenoxolone<p>carvedilol increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>carbidopa<p>carbidopa increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.</p></li><li>celecoxib<p>celecoxib will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>carvedilol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>celiprolol<p>carvedilol and celiprolol both increase  serum potassium. Use Caution/Monitor.</p></li><li>ceritinib<p>carvedilol increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>chloroquine<p>chloroquine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>chlorothiazide<p>carvedilol increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>chlorthalidone<p>carvedilol increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>carvedilol and choline magnesium trisalicylate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>choline magnesium trisalicylate decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>cimetidine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>citalopram<p>citalopram increases levels of carvedilol by decreasing metabolism. Use Caution/Monitor.</p></li><li>clevidipine<p>carvedilol and clevidipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>clobazam<p>clobazam will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. </p></li><li>cobicistat<p>cobicistat will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of carvedilol by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cyclopenthiazide<p>carvedilol increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dabigatran<p>carvedilol will increase the level or effect of dabigatran by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Atrial fibrillation: Avoid coadministering dabigatran with P-gp inhibitors if CrCl &lt;30 mL/min.  DVT/PE treatment: Avoid coadministering dabigatran with P-gp inhibitors if CrCl &lt;50 mL/min</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of carvedilol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>darifenacin<p>darifenacin will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>desflurane<p>desflurane, carvedilol.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>desvenlafaxine<p>desvenlafaxine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses &lt;100 mg</p></li><li>dichlorphenamide<p>dichlorphenamide and carvedilol both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>carvedilol and diclofenac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>diclofenac decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>diflunisal<p>carvedilol and diflunisal both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>diflunisal decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>digoxin<p>carvedilol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol increases levels of digoxin by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>carvedilol increases levels of digoxin by decreasing renal clearance. Use Caution/Monitor.<span><br><br></span>carvedilol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>diltiazem<p>carvedilol and diltiazem both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>diphenhydramine<p>diphenhydramine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>divalproex sodium<p>divalproex sodium will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>dobutamine<p>carvedilol increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of dobutamine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>dopexamine<p>carvedilol increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of dopexamine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>doxazosin<p>doxazosin and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>drospirenone<p>carvedilol and drospirenone both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>dyphylline<p>carvedilol, dyphylline. Other (see comment). Use Caution/Monitor. 
Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.</p></li><li>eliglustat<p>eliglustat increases levels of carvedilol by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.<span><br><br></span>eliglustat increases levels of carvedilol by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of carvedilol by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.<span><br><br></span>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of carvedilol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.</p></li><li>enflurane<p>enflurane, carvedilol.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>ephedrine<p>carvedilol increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of ephedrine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>ephedrine (pulmonary)<p>carvedilol increases and ephedrine (pulmonary) decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .<span><br><br></span>carvedilol decreases effects of ephedrine (pulmonary) by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>epinephrine<p>carvedilol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>epinephrine racemic<p>carvedilol increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>eprosartan<p>eprosartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, eprosartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>esmolol<p>carvedilol and esmolol both increase  serum potassium. Use Caution/Monitor.</p></li><li>ethacrynic acid<p>carvedilol increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ethanol<p>ethanol increases levels of carvedilol by Other (see comment). Use Caution/Monitor. 
Comment: ETOH may affect the release rate of extended-release carvedilol (Coreg CR), resulting in  higher peak plasma concentration.  Separate by 2 hr.  Immediate-release carvedilol (Coreg) not affected.</p></li><li>ether<p>carvedilol, ether.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both beta blockers and ether depress the myocardium; consider lowering beta blocker dose if ether used for anesthesia.</p></li><li>etodolac<p>carvedilol and etodolac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>etodolac decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>etomidate<p>etomidate, carvedilol.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>etoricoxib<p>carvedilol and etoricoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>etoricoxib decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>etravirine<p>etravirine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>felbamate<p>felbamate will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>felodipine<p>carvedilol and felodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>fenbufen<p>carvedilol and fenbufen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>fenbufen decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>fenoprofen<p>carvedilol and fenoprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>fenoprofen decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>fingolimod<p>carvedilol increases effects of fingolimod by pharmacodynamic synergism. Use Caution/Monitor. Both medications decrease heart rate. Monitor patients on concomitant therapy, particularly in the first 6 hours after fingolimod is initiated or after a treatment interruption of at least two weeks,  for bradycardia and atrioventricular block. To identify underlying risk factors of bradycardia and AV block, obtain a new or recent ECG in patients using beta-blockers prior to starting fingolimod.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>fluoxetine<p>fluoxetine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>flurbiprofen<p>carvedilol and flurbiprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>flurbiprofen decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>formoterol<p>carvedilol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>furosemide<p>carvedilol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>gentamicin<p>carvedilol increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>haloperidol<p>haloperidol will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>hexobarbital decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.</p></li><li>hydralazine<p>hydralazine increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.<span><br><br></span>carvedilol increases effects of hydralazine by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.</p></li><li>hydrochlorothiazide<p>carvedilol increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ibuprofen<p>carvedilol and ibuprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ibuprofen decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>imatinib<p>imatinib will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>imatinib will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>indapamide<p>carvedilol increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>indomethacin<p>carvedilol and indomethacin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>indomethacin decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>insulin degludec<p>carvedilol, insulin degludec. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).</p></li><li>insulin degludec/insulin aspart<p>carvedilol, insulin degludec/insulin aspart. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).</p></li><li>insulin inhaled<p>carvedilol, insulin inhaled. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).</p></li><li>irbesartan<p>irbesartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, irbesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>isoproterenol<p>carvedilol increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of isoproterenol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>isradipine<p>carvedilol and isradipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>ivabradine<p>ivabradine, carvedilol.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Most patients receiving ivabradine will also be treated with a beta-blocker. The risk of bradycardia increases with  coadministration of drugs that slow heart rate (eg, digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine with other negative chronotropes.</p></li><li>ketamine<p>ketamine, carvedilol.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>ketoprofen<p>carvedilol and ketoprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ketoprofen decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>ketorolac<p>carvedilol and ketorolac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ketorolac decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>ketorolac intranasal<p>carvedilol and ketorolac intranasal both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ketorolac intranasal decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>labetalol<p>carvedilol and labetalol both increase  serum potassium. Use Caution/Monitor.</p></li><li>lacidipine<p>carvedilol and lacidipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>leflunomide<p>leflunomide will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>lercanidipine<p>carvedilol and lercanidipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.<span><br><br></span>carvedilol decreases levels of lercanidipine by Other (see comment). Use Caution/Monitor. 
Comment: Beta blockers decr bioavailability of lercanidipine by 50% d/t reduction in hepatic blood flow. Combo safe to use, but dose adjustment may be necessary.</p></li><li>levalbuterol<p>carvedilol increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of levalbuterol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>levodopa<p>levodopa increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.</p></li><li>lomitapide<p>lomitapide increases levels of carvedilol by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.</p></li><li>lorcaserin<p>lorcaserin will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lornoxicam<p>carvedilol and lornoxicam both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>lornoxicam decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>losartan<p>losartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, carvedilol. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C9 substrates. .</p></li><li>lurasidone<p>lurasidone increases effects of carvedilol by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.</p></li><li>maraviroc<p>maraviroc will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>marijuana<p>marijuana will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>meclofenamate<p>meclofenamate decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.<span><br><br></span>carvedilol and meclofenamate both increase  serum potassium. Use Caution/Monitor.</p></li><li>mefenamic acid<p>carvedilol and mefenamic acid both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>mefenamic acid decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>mefloquine<p>mefloquine increases levels of carvedilol by decreasing metabolism. Use Caution/Monitor. Risk of arrhythmia.</p></li><li>meloxicam<p>carvedilol and meloxicam both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>meloxicam decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>mephobarbital decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of mephobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.</p></li><li>metaproterenol<p>carvedilol increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of metaproterenol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>methyclothiazide<p>carvedilol increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>metolazone<p>carvedilol increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metoprolol<p>carvedilol and metoprolol both increase  serum potassium. Use Caution/Monitor.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>mirabegron<p>mirabegron will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>moxisylyte<p>moxisylyte and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>nabumetone<p>carvedilol and nabumetone both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>nabumetone decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>nadolol<p>carvedilol and nadolol both increase  serum potassium. Use Caution/Monitor.</p></li><li>naproxen<p>carvedilol and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>nateglinide<p>nateglinide will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>nebivolol<p>carvedilol and nebivolol both increase  serum potassium. Use Caution/Monitor.</p></li><li>nicardipine<p>carvedilol and nicardipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>nifedipine<p>carvedilol and nifedipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>nilotinib will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>nintedanib<p>carvedilol increases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy.</p></li><li>nisoldipine<p>carvedilol and nisoldipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>nitisinone<p>nitisinone will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal, carvedilol.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Beta-blockers blunt the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effects. If beta-blockers are used with nitroglycerin in patients with angina pectoris, additional hypotensive effects may occur.</p></li><li>norepinephrine<p>carvedilol increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of norepinephrine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>olmesartan<p>olmesartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>olodaterol inhaled<p>carvedilol, olodaterol inhaled.
Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor. Beta-blockers and olodaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of carvedilol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>oxaprozin<p>carvedilol and oxaprozin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>oxaprozin decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>oxymetazoline topical<p>oxymetazoline topical increases and carvedilol decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>parecoxib<p>parecoxib will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>carvedilol and parecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>parecoxib decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>penbutolol<p>carvedilol and penbutolol both increase  serum potassium. Use Caution/Monitor.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>pentobarbital decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of pentobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.</p></li><li>perphenazine<p>perphenazine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>phenobarbital decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of phenobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.</p></li><li>phenoxybenzamine<p>phenoxybenzamine and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>phentolamine<p>phentolamine and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>pindolol<p>carvedilol and pindolol both increase  serum potassium. Use Caution/Monitor.</p></li><li>pirbuterol<p>carvedilol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of pirbuterol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>piroxicam<p>carvedilol and piroxicam both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>piroxicam decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>ponatinib<p>ponatinib increases levels of carvedilol by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>potassium acid phosphate<p>carvedilol and potassium acid phosphate both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>potassium chloride<p>carvedilol and potassium chloride both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>potassium citrate<p>carvedilol and potassium citrate both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>prazosin<p>prazosin and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>primidone<p>primidone will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>primidone decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of primidone.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.</p></li><li>propafenone<p>propafenone will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>propofol<p>propofol, carvedilol.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>propranolol<p>carvedilol and propranolol both increase  serum potassium. Use Caution/Monitor.</p></li><li>quinacrine<p>quinacrine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ranolazine<p>ranolazine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>reserpine<p>reserpine increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>rifabutin<p>rifabutin decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>rifampin decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>rifapentine decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor.</p></li><li>rifaximin<p>carvedilol increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>sacubitril/valsartan<p>sacubitril/valsartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, sacubitril/valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>salicylates (non-asa)<p>carvedilol and salicylates (non-asa) both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>salicylates (non-asa) decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>salmeterol<p>carvedilol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>salsalate<p>carvedilol and salsalate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>salsalate decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>saquinavir<p>saquinavir, carvedilol.
Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Use alternatives if available. Increased risk of PR prolongation and cardiac arrhythmias.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>secobarbital decreases levels of carvedilol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of secobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.</p></li><li>sertraline<p>sertraline will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>sevoflurane<p>sevoflurane, carvedilol.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>sildenafil<p>carvedilol will increase the level or effect of sildenafil by  decreasing hepatic clearance. Use Caution/Monitor. Sildenafil clearance decreased by ~34% when coadministered with beta-blockers</p></li><li>silodosin<p>silodosin and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>sodium bicarbonate<p>sodium bicarbonate decreases levels of carvedilol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>sodium citrate/citric acid<p>sodium citrate/citric acid decreases levels of carvedilol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>sotalol<p>carvedilol and sotalol both increase  serum potassium. Use Caution/Monitor.</p></li><li>spironolactone<p>carvedilol and spironolactone both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>succinylcholine<p>carvedilol and succinylcholine both increase  serum potassium. Use Caution/Monitor.</p></li><li>sulfamethoxazole<p>sulfamethoxazole will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>sulfasalazine<p>carvedilol and sulfasalazine both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sulfasalazine decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>sulindac<p>carvedilol and sulindac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sulindac decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>tacrine<p>carvedilol, tacrine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive bradycardia.</p></li><li>tadalafil<p>tadalafil increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>telmisartan<p>telmisartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, telmisartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>terazosin<p>terazosin and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>terbutaline<p>carvedilol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>carvedilol decreases effects of terbutaline by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>theophylline<p>carvedilol, theophylline. Other (see comment). Use Caution/Monitor. 
Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.</p></li><li>thioridazine<p>thioridazine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ticlopidine<p>ticlopidine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>timolol<p>carvedilol and timolol both increase  serum potassium. Use Caution/Monitor.</p></li><li>tipranavir<p>tipranavir will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>tolfenamic acid<p>carvedilol and tolfenamic acid both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>tolfenamic acid decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>tolmetin<p>carvedilol and tolmetin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>tolmetin decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>tolvaptan<p>carvedilol and tolvaptan both increase  serum potassium. Use Caution/Monitor.</p></li><li>torsemide<p>carvedilol increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>triamterene<p>carvedilol and triamterene both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>valproic acid<p>valproic acid will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>valsartan<p>valsartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>vemurafenib<p>vemurafenib increases levels of carvedilol by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>venlafaxine<p>venlafaxine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>verapamil<p>carvedilol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>vismodegib<p>carvedilol will increase the level or effect of vismodegib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Vismodegib is a substrate of efflux transporter P-glycoprotein (P-gp); coadministration with P-gp inhibitors increase vismodegib systemic exposure</p></li><li>voriconazole<p>voriconazole will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>xipamide<p>xipamide increases effects of carvedilol by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>zotepine<p>zotepine and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li>